Systemic inflammation and proinflammatory interleukin‐17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission
暂无分享,去创建一个
A. Santos-Silva | M. Neuparth | J. B. Proença | S. Coimbra | P. Rocha-Pereira | H. Oliveira | A. Figueiredo | M. Neuparth